business

business

Federal Reserve Board withdraws 2023 policy statement and issues new policy statement regarding the treatment of certain Board-supervised banks that facilitates responsible innovation - Federal Reserve Board (.gov)

Federal Reserve Withdraws Policy Statement, Issues New One on Bank Treatment In a significant shift, the Federal Reserve Board has withdrawn its 2023 policy statement and issued a new one. The move is related to the treatment of certain board-supervised banks, with the goal of facilitating responsible innovation. Background The

By Lau Chi Fung

business

Insmed Provides Clinical and Business Update - Insmed Incorporated Investor Relations

Insmed Announces Discontinuation of CRSsNP Program Following Negative Phase 2b BiRCh Study Results In a significant update to its clinical trial program, Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing treatments for rare respiratory diseases, announced that it is discontinuing its Chronic Respiratory Susceptibility Non-Pulmonary (CRSsNP) program following

By Lau Chi Fung

business

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib) - Johnson & Johnson

Johnson & Johnson Announces FDA Approval for RYBREVANT FASPRO Date: December 17, 2025 Location: Horsham, PA Company: Johnson & Johnson (NYSE: JNJ) In a significant development in the world of pharmaceuticals, Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO, a

By Lau Chi Fung